To our knowledge, our study is the first to demonstrate that ADAM17 plays a key role in the pathogenesis of doxorubicin-induced cardiomyopathy and offers a potential therapeutic target for this intractable disorder. The gene discussed is ADAM17; the disease is cardiomyopathy.